“O Hashem my God, I cried unto Thee, and Thou didst heal me.” Psalms 30:3 (The Israel Bible™)
A Tel Aviv University study published last month in the Journal of Alzheimer’s Disease suggests a new possible culprit in causing Alzheimer’s: the APOE gene. Like Dr. Jekyll and Mr. Hyde, APOE has two faces: a healthy form called APOE3 and a disease-related pathological form called APOE4. Now, according to a TAU press release, researchers have developed a novel mechanism and approach with which to convert the “bad” APOE4 to the “good” APOE3.
The research was led by Prof. Daniel (Danny) M. Michaelson, Director of the Eichenbaum Laboratory of Alzheimer’s Disease Research and incumbent of the Myriam Lebach Chair in Molecular Neurodegeneration at TAU’s Faculty of Life Sciences, together with Anat Boehm-Cagan, the Eleanore and Harold Foonberg Doctoral Fellow in Alzheimer’s Disease Research, and in collaboration with the commercial company Artery Ltd., based in California.
For the last 20 years, researchers have focused on amyloid beta peptides and the “plaque” they sprout in diseased brains as the main target of Alzheimer’s research. But the pace of progress in treating — not to mention curing — the debilitating, neurodegenerative disease has been painfully slow.
Prof. Michaelson said that “APOE4 is a very important and understudied target. It is expressed in more than 60 percent of Alzheimer’s patients. Anti-APOE4 treatments are thus expected to have a major impact on the patient population.”
He explained that “the normal APOE gene provides the interface that moves lipids — naturally occurring molecules that include fats, cholesterol, fat-soluble vitamins and other components essential to the health of cells — in and out of cells, whereas the healthy APOE3 does so effectively, the bad form — APOE4 — is impaired.”
Prof. Michaelson and other groups have discovered in earlier research that the bad APOE4 and the good APOE3 differed in their interactions with lipid cargo, so that, for example, the good APOE3 is associated with substantially more lipids than APOE4.
The researchers devised an experimental approach to measure the “bad” features of APOE4, utilizing genetically manipulated mice expressing either good or bad forms of APOE. Mice with APOE4 exhibited impaired learning and memory, damaged brain synapses, and an accumulation of phosphorylated tau and a-beta molecules — two pathological hallmarks of Alzheimer’s. Could there be a way of turning the bad gene good?
“Once this model was established and the pathological effects of APOE4 could be reproduced in mice, we could test therapeutic approaches and tackle APOE4 itself,” Prof. Michaelson said. “Because we know that APOE4 carries fewer lipids, we looked at the means of counteracting the lipidation deficiency.”
“We focused on an enzymatic machinery called ABCA1 that loads lipid cargo onto APOE4,” he continued. “We found that the impaired lipidation of APOE4 could be successfully reversed by activating ABCA1. Most importantly, we discovered that this increased lipidation of APOE4 reversed the behavioral impairments and brain damage seen in non-treated APOE4 mice.”
In the course of administering the treatment, the researchers found that mice which prior to treatment exhibited disoriented behavior and seemed “lost,” following treatment were able to locate a submerged island in the middle of an artificial pond. Mice who had forgotten familiar objects — like Coca Cola bottles — suddenly exhibited sharp object recognition.
“Is there really a magic bullet? One treatment that covers all aspects of Alzheimer’s? Not likely,” said Prof. Michaelson. “Therefore there is a need to define specific subpopulations and to develop treatments targeted at genetic risk factors of the disease, like APOE4, which affects more than half of the Alzheimer’s population.”